Large study finds statins offer no added depression benefit despite earlier hopes

Statins are among the world's most widely prescribed medicines. Doctors reach for them when cholesterol climbs, aiming to head off heart attacks and strokes by reducing the buildup of plaque in arteries. But over the past decade, smaller studies began suggesting something unexpected: these cholesterol-lowering drugs might also ease depression. The logic was tantalizing. Depression and obesity often travel together, and obese patients typically have elevated cholesterol. If statins could address both conditions at once, physicians could treat two serious health problems with a single medication. That possibility prompted researchers at Charité – Universitätsmedizin Berlin to mount a rigorous test.

Christian Otte, director of the Department of Psychiatry and Neurosciences at Charité, led the effort. The team enrolled 161 patients who carried both diagnoses: depression and obesity. For twelve weeks, all participants received escitalopram, a standard antidepressant. Half also took simvastatin, a cholesterol-lowering drug. The other half received a placebo. Neither the researchers nor the patients knew who was getting what—a randomized, double-blind design meant to produce trustworthy results. The researchers measured depression severity using clinical interviews and questionnaires at the start and end of the trial. They also drew blood to track cholesterol levels and C-reactive protein, a marker of inflammation in the body.

The hypothesis rested on inflammation. People with obesity and depression often show elevated inflammatory markers in their blood, and for some, inflammation may actually drive depression itself. Statins reduce inflammation as a side effect of lowering cholesterol. So the question became: if statins tamped down inflammation, might that improvement also ease depression symptoms?

The results offered no support for that theory. Over the twelve weeks, depression improved across the board—patients in both groups felt better. Statins did their job on cholesterol and inflammation; C-reactive protein levels dropped noticeably, and blood lipid profiles improved as expected. But when the researchers compared the two groups, the statin recipients showed no greater reduction in depression than those on placebo. The anti-inflammatory benefit did not translate into an antidepressive one.

Otte and his team concluded that statins should remain what they have always been: a tool for cardiovascular prevention, not psychiatric treatment. Traditional antidepressants remain the standard of care for depression. The researchers recommend that physicians continue prescribing statins according to current guidelines—to lower cardiovascular risk—even for patients who are depressed. The distinction matters because it closes a door that earlier, smaller studies had left open. Doctors now have clearer guidance: do not expect statins to lighten a patient's mood.

The work does not end here. Otte's team plans to conduct deeper molecular and cellular analysis of the blood samples collected during the trial, hunting for patterns that might explain why inflammation reduction did not help depression in this population. They are also pursuing other strategies to better treat patients caught between multiple conditions—those struggling with depression alongside obesity, cardiovascular risk, or other chronic illnesses. The findings appear in JAMA Psychiatry.